Short radiation plus ivonescimab and chemo before rectal cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment approach for locally advanced rectal cancer that is pMMR/MSS. It combines a short course of radiation before surgery with a drug called ivonescimab and chemotherapy, aiming to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You can do your daily activities without help (ECOG 0 or 1).
- You have a type of rectal cancer called 'adenocarcinoma' that is pMMR or MSS (a protein or gene test result).
- Your cancer is stage II or III, and the tumor is within about 12 cm of the anal opening.
- You have not had any prior treatment for rectal cancer (like radiation, chemo, or immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving targeted radiation, chemotherapy, and immunotherapy before surgery to shrink locally advanced rectal cancer. It aims to improve treatment results for patients whose tumors have not spread but are at high risk of coming back.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (ivonescimab) for people with locally advanced rectal cancer. It aims to see if this approach can shrink tumors before surgery, especially for high-risk cases.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a new combination of treatments before surgery for locally advanced rectal cancer. You would receive short-course radiation, then an immunotherapy drug (camrelizumab) plus a PARP inhibitor (fluzoparib) and chemotherapy, to shrink the tumor and make surgery more successful.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.